thalidomide has been researched along with Cardiovascular Diseases in 14 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis." | 9.24 | Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). ( Cather, JC; Chen, R; Crowley, J; Day, RM; Ferrándiz, C; Goncalves, J; Joly, P; Papp, KA; Peris, K; Shah, K; Thaçi, D, 2017) |
| " In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens." | 9.15 | Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Caravita, T; Carella, AM; Cavo, M; Cellini, C; Crippa, C; Elice, F; Evangelista, A; Galli, M; Gentilini, F; Magarotto, V; Marasca, R; Montefusco, V; Morabito, F; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Polloni, C; Pulini, S; Ria, R; Romano, A; Rossi, D; Tacchetti, P; Tosi, P; Zamagni, E; Zambello, R, 2011) |
| "Bortezomib has been shown to be highly active in MM patients with RI." | 5.36 | Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. ( Baldini, L; Boccadoro, M; Bringhen, S; Callea, V; Casulli, AF; Catalano, L; Cavo, M; Ciolli, S; Di Raimondo, F; Galimberti, S; Gentile, M; Mannina, D; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Palumbo, A; Petrucci, MT; Pinotti, G; Piro, E; Tosi, P, 2010) |
| "Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis." | 5.24 | Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). ( Cather, JC; Chen, R; Crowley, J; Day, RM; Ferrándiz, C; Goncalves, J; Joly, P; Papp, KA; Peris, K; Shah, K; Thaçi, D, 2017) |
| " In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens." | 5.15 | Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Caravita, T; Carella, AM; Cavo, M; Cellini, C; Crippa, C; Elice, F; Evangelista, A; Galli, M; Gentilini, F; Magarotto, V; Marasca, R; Montefusco, V; Morabito, F; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Polloni, C; Pulini, S; Ria, R; Romano, A; Rossi, D; Tacchetti, P; Tosi, P; Zamagni, E; Zambello, R, 2011) |
| "Pomalidomide entered treatment for the second relapse in 2015 (11% of patients)." | 1.46 | Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey. ( Goldschmidt, H; Kellermann, L; Knauf, W; Kohnke, J; Merz, M; Poenisch, W; Tischler, HJ, 2017) |
| "Bortezomib has been shown to be highly active in MM patients with RI." | 1.36 | Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. ( Baldini, L; Boccadoro, M; Bringhen, S; Callea, V; Casulli, AF; Catalano, L; Cavo, M; Ciolli, S; Di Raimondo, F; Galimberti, S; Gentile, M; Mannina, D; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Palumbo, A; Petrucci, MT; Pinotti, G; Piro, E; Tosi, P, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 6 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Arias de la Rosa, I | 1 |
| López-Montilla, MD | 1 |
| Román-Rodríguez, C | 1 |
| Pérez-Sánchez, C | 1 |
| Gómez-García, I | 1 |
| López-Medina, C | 1 |
| Ladehesa-Pineda, ML | 1 |
| Ábalos-Aguilera, MDC | 1 |
| Ruiz, D | 1 |
| Patiño-Trives, AM | 1 |
| Luque-Tévar, M | 1 |
| Añón-Oñate, I | 1 |
| Pérez-Galán, MJ | 1 |
| Guzmán-Ruiz, R | 1 |
| Malagón, MM | 1 |
| López-Pedrera, C | 1 |
| Escudero-Contreras, A | 1 |
| Collantes-Estévez, E | 1 |
| Barbarroja, N | 1 |
| Pina Vegas, L | 3 |
| Claudepierre, P | 3 |
| Sbidian, E | 3 |
| Suruki, RY | 1 |
| Desai, RJ | 1 |
| Davis, KJ | 1 |
| Berlin, JA | 1 |
| Gagne, JJ | 1 |
| Ouyang, F | 1 |
| Le Corvoisier, P | 1 |
| Penso, L | 1 |
| Paul, M | 1 |
| Merz, M | 1 |
| Kellermann, L | 1 |
| Poenisch, W | 1 |
| Tischler, HJ | 1 |
| Kohnke, J | 1 |
| Knauf, W | 1 |
| Goldschmidt, H | 1 |
| Crowley, J | 1 |
| Thaçi, D | 1 |
| Joly, P | 1 |
| Peris, K | 1 |
| Papp, KA | 1 |
| Goncalves, J | 1 |
| Day, RM | 1 |
| Chen, R | 1 |
| Shah, K | 1 |
| Ferrándiz, C | 1 |
| Cather, JC | 1 |
| Merlini, G | 1 |
| Palladini, G | 1 |
| Li, W | 1 |
| Garcia, D | 1 |
| Cornell, RF | 1 |
| Gailani, D | 1 |
| Laubach, J | 1 |
| Maglio, ME | 1 |
| Richardson, PG | 1 |
| Moslehi, J | 1 |
| Fernández Salazar, LI | 1 |
| Velayos Jiménez, B | 1 |
| Fernández Galante, I | 1 |
| Aller de la Fuente, R | 1 |
| González Hernández, JM | 1 |
| Morabito, F | 2 |
| Gentile, M | 1 |
| Ciolli, S | 1 |
| Petrucci, MT | 1 |
| Galimberti, S | 1 |
| Mele, G | 1 |
| Casulli, AF | 1 |
| Mannina, D | 1 |
| Piro, E | 1 |
| Pinotti, G | 1 |
| Palmieri, S | 1 |
| Catalano, L | 1 |
| Callea, V | 2 |
| Offidani, M | 2 |
| Musto, P | 1 |
| Bringhen, S | 2 |
| Baldini, L | 2 |
| Tosi, P | 2 |
| Di Raimondo, F | 1 |
| Boccadoro, M | 2 |
| Palumbo, A | 2 |
| Cavo, M | 2 |
| Prommer, EE | 1 |
| Twycross, R | 1 |
| Mihalyo, M | 1 |
| Wilcock, A | 1 |
| Zamagni, E | 1 |
| Romano, A | 1 |
| Patriarca, F | 1 |
| Rossi, D | 1 |
| Gentilini, F | 1 |
| Crippa, C | 1 |
| Galli, M | 1 |
| Nozzoli, C | 1 |
| Ria, R | 1 |
| Marasca, R | 1 |
| Montefusco, V | 1 |
| Elice, F | 1 |
| Pulini, S | 1 |
| Carella, AM | 1 |
| Zambello, R | 1 |
| Benevolo, G | 1 |
| Magarotto, V | 1 |
| Tacchetti, P | 1 |
| Pescosta, N | 1 |
| Cellini, C | 1 |
| Polloni, C | 1 |
| Evangelista, A | 1 |
| Caravita, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study to Evaluate the Efficacy and Safety of Apremilast in Patients of Chronic and Recurrent Erythema Nodosum Leprosum[NCT04822909] | Phase 4 | 10 participants (Actual) | Interventional | 2019-09-15 | Completed | ||
| Efficacy and Safety of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis[NCT06032858] | Phase 4 | 30 participants (Actual) | Interventional | 2022-03-06 | Completed | ||
| An Observational Study of Cardiovascular Complications of Carfilzomib Treatment in Clinical Practice[NCT03543579] | 46 participants (Anticipated) | Observational | 2017-03-23 | Active, not recruiting | |||
| Thrombosis in Newly Diagnosed Multiple Myeloma Patients: a Clinical Audit of Intermediate Dose Low Molecular Weight Heparin[NCT05541978] | 140 participants (Actual) | Observational | 2022-09-01 | Completed | |||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for thalidomide and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Humans; Immunologic Factors; Lenalidomide; Multiple | 2017 |
Thalidomide.
Topics: Abnormalities, Drug-Induced; Cardiovascular Diseases; Chronic Disease; Dose-Response Relationship, D | 2011 |
2 trials available for thalidomide and Cardiovascular Diseases
| Article | Year |
|---|---|
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Depression; Diarrhea; Femal | 2017 |
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Depression; Diarrhea; Femal | 2017 |
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Depression; Diarrhea; Femal | 2017 |
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Depression; Diarrhea; Femal | 2017 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
10 other studies available for thalidomide and Cardiovascular Diseases
| Article | Year |
|---|---|
The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Cardiovascular Diseases; Cross-Sectional Studies; Humans | 2022 |
Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study: Reply.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Biological Products; Cardiovascular D | 2022 |
Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Biological Products; Cardiovascular D | 2022 |
Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Biological Products; Cardiovascular D | 2022 |
Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study: Reply.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Biological Products; Cardiovascular D | 2022 |
Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.
Topics: Adult; Antirheumatic Agents; Arthritis, Psoriatic; Biological Factors; Biological Products; Cardiova | 2022 |
Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cardiova | 2017 |
Light chain amyloidosis: the heart of the problem.
Topics: Amyloidosis; Animals; Cardiovascular Diseases; Death; Dexamethasone; Humans; Lenalidomide; Thalidomi | 2013 |
[Efficacy of thalidomide in digestive bleeding caused by angiodysplasias].
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Cardiovascular Diseases; Cerebellar Neoplasms; Cerebe | 2009 |
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2010 |